Last reviewed · How we verify

NCT06874920

Outcomes of Empiric Antibiotic Therapy Based on Hospital Antibiograms in Organ Transplant Recipients with Bacteraemia

ENROLLING BY INVITATION Last updated 13 March 2025
What this trial tests

trial testing No intervention (observational study) in Bacteremia in 150 participants. Enrolling by invitation.

Timeline
3 December 2024
Primary endpoint
1 January 2026
1 January 2027

Quick facts

Lead sponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment150
Start date3 December 2024
Primary completion1 January 2026
Estimated completion1 January 2027
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Who can join

18 and older, any sex, with Bacteremia or Transplant Recipient. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this observational study is to examine how using the hospital cumulative antibiogram to guide empirical antibiotic therapy affects outcomes in patients with bloodstream infections who have undergone solid organ transplants. The key question is: does the use of a hospital cumulative antibiogram reduce mortality and improve outcomes in these patients?

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention (observational study)

Trials testing the same drug.

Other recruiting trials for Bacteremia

Currently open trials in the same condition.

Other Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06874920.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing